GSK plc (GSK.L) Tuesday reported positive headline results from the phase 3 study dubbed GLISTEN evaluating Linerixibat in adults with cholestatic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease.
The study met its primary goal by achieving a statistically significant improvement in itch in patients treated with Linerixibat compared with those on placebo.
For comments and feedback: editorial@rttnews.com